Drug Profile
Research programme: small molecule therapeutics - Alexion AstraZeneca Rare Disease /X-Chem
Latest Information Update: 29 Jul 2021
Price :
$50
*
At a glance
- Originator Alexion Pharmaceuticals; X-Chem
- Developer X-Chem
- Class Small molecules
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 21 Jul 2021 Alexion Pharmaceuticals has been acquired by AstraZeneca and changed its name to Alexion AstraZeneca Rare Disease
- 28 Jan 2019 No recent reports of development identified for research development in Unspecified in USA
- 12 Dec 2014 Early research in Undefined indication in USA (unspecified route)